Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) has entered into a definitive agreement with Eli Lilly and Company which allows Regen to receive compounds from Lilly for drug discovery purposes and allows Regen to share structural information on compounds of mutual interest.

The agreement also grants to Lilly an option to negotiate an agreement with Regen including but not restricted to a compound purchase agreement, a license agreement, or a research collaboration agreement for further research and development of material of mutual interest.

“Lilly’s Open Innovation Drug Discovery Program is visionary,” said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma, Inc. “They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals.”

As a consequence of this agreement, Regen will examine 21,000 Lilly-owned compounds in its NR2F6 high-throughput screening program as it attempts to identify activators and inhibitors of this protein.  Regen will share the experimental data with Lilly and the two companies will jointly decide on next steps.

NR2F6 is a molecular switch known as an “orphan nuclear receptor,” which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate.  Regen has filed numerous patents covering means of manipulating NR2F6 in oncology and immunology.  Issued US Patent # 9091696 was granted to Regen and covers means of screening small molecules such as is being done in this program.  Cancer, as well as autoimmune diseases such as lupus, rheumatoid arthritis and irritable bowel syndrome, is likely to be controlled by modifying NR2F6 activity.

Regen is currently in the process of screening more than 70,000 compounds in an effort to identify activators and inhibitors of NR2F6. Two activators have been identified and preliminary work on inhibitors is currently underway.

About Regen BioPharma, Inc.

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com

http://www.regenbiopharmainc.com

By admin

PennyStockPlay is committed to providing our members with the most informative and accurate penny stock trading information available on the Internet today. The team at PennyStockPlay is dedicated to turning even the most novice trader into a seasoned one. No one can guarantee gains, and if they do they are lying. There is always a minimum level of risk, as small as it can be, it is still present. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost, and current performance may be lower or higher than the performance quoted. We believe that the well-educated investor is a wealthy one, so subscribe to our newsletter by entering your email address in the opt-in box below and let us help you build a stock portfolio that will be the envy of all of your peers!

Leave a Reply

Your email address will not be published. Required fields are marked *